HOME HELP CONTACT US SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) All Versions of this Article: JOE-08-0354v1 199/3/399    most recent Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in Web of Science Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Web of Science (2) Citing Articles via Google Scholar Google Scholar Articles by Caricilli, A. M Articles by Saad, M. J A Search for Related Content PubMed PubMed Citation Articles by Caricilli, A. M Articles by Saad, M. J A

Department of Internal Medicine, State University of Campinas, 13081-970 Campinas, SP, Brazil

(Correspondence should be addressed to M J A Saad who is now at Departamento de Clínica Médica, FCM-UNICAMP, Cidade Universitária Zeferino Vaz, 13081-970 Campinas, SP, Brazil; Email: msaad{at}fcm.unicamp.br)

The aims of the present study were to investigate the expression of toll-like receptor 2 (TLR2) in muscle and white adipose tissue (WAT) of diet-induced obesity (DIO) mice, and also the effects of its inhibition, with the use of TLR2 antisense oligonucleotide (ASON), on insulin sensitivity and signaling. The expression of TLR2 was increased in muscle and WAT of DIO mice, compared with those that received standard chow. Inhibition of TLR2 in DIO mice, by TLR2 ASON, improved insulin sensitivity and signaling in muscle and WAT. In addition, data show that the inhibition of TLR2 expression prevents the activation of IKBKB, MAPK8, and serine phosphorylation of IRS1 in DIO mice, suggesting that TLR2 is a key modulator of the crosstalk between inflammatory and metabolic pathways. We, therefore, suggest that a selective interference with TLR2 presents an attractive opportunity for the treatment of insulin resistance in obesity and type 2 diabetes.

This article has been cited by other articles:

				T. Coll, X. Palomer, F. Blanco-Vaca, J. C. Escola-Gil, R. M. Sanchez, J. C. Laguna, and M. Vazquez-Carrera Cyclooxygenase 2 Inhibition Exacerbates Palmitate-Induced Inflammation and Insulin Resistance in Skeletal Muscle Cells Endocrinology, February 1, 2010; 151(2): 537 - 548. [Abstract] [Full Text] [PDF]

				T. Romanatto, E. A. Roman, A. P. Arruda, R. G. Denis, C. Solon, M. Milanski, J. C. Moraes, M. L. Bonfleur, G. R. Degasperi, P. K. Picardi, et al. Deletion of Tumor Necrosis Factor-{alpha} Receptor 1 (TNFR1) Protects against Diet-induced Obesity by Means of Increased Thermogenesis J. Biol. Chem., December 25, 2009; 284(52): 36213 - 36222. [Abstract] [Full Text] [PDF]

				H. Ghanim, S. Abuaysheh, C. L. Sia, K. Korzeniewski, A. Chaudhuri, J. M. Fernandez-Real, and P. Dandona Increase in Plasma Endotoxin Concentrations and the Expression of Toll-Like Receptors and Suppressor of Cytokine Signaling-3 in Mononuclear Cells After a High-Fat, High-Carbohydrate Meal: Implications for insulin resistance Diabetes Care, December 1, 2009; 32(12): 2281 - 2287. [Abstract] [Full Text] [PDF]

				M. Jagannathan, H. Hasturk, Y. Liang, H. Shin, J. T. Hetzel, A. Kantarci, D. Rubin, M. E. McDonnell, T. E. Van Dyke, L. M. Ganley-Leal, et al. TLR Cross-Talk Specifically Regulates Cytokine Production by B Cells from Chronic Inflammatory Disease Patients J. Immunol., December 1, 2009; 183(11): 7461 - 7470. [Abstract] [Full Text] [PDF]

				L. A. J. O'Neill, C. E. Bryant, and S. L. Doyle Therapeutic Targeting of Toll-Like Receptors for Infectious and Inflammatory Diseases and Cancer Pharmacol. Rev., June 1, 2009; 61(2): 177 - 197. [Abstract] [Full Text] [PDF]